Payment overview · 2025
General Payments
$581.13
37 reported records · 9 companies
Healthcare provider profile · identity verified
Sergio Diaz, PHYSICIAN ASSISTANT
Physician Assistants & Advanced Practice Nursing Providers|Physician Assistant · MCALLEN, TX · NPI 1740423474
Verified facts
What the public records show
CMS Open Payments records show Sergio Diaz, PHYSICIAN ASSISTANT received $581.13 in general payments during 2025 across 37 reported records.
Novo Nordisk Inc accounted for 25.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Ozempic, Rexulti, Rybelsus, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Vraylar by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Prolia by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 246 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $145.42 | 25.0% | 10 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $138.30 | 23.8% | 12 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $86.56 | 14.9% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $56.96 | 9.8% | 3 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $42.72 | 7.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.96 | 5.7% | 2 | 2025 |
| Indivior Inc. | Unresolved — no canonical attribution shown | $28.66 | 4.9% | 1 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $26.95 | 4.6% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $22.60 | 3.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $581.13 | 37 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $138.30 | 12 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $120.70 | 11 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $105.55 | 7 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $65.96 | 4 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $49.89 | 4 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $42.72 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $39.57 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $32.96 | 2 | 2025 |
Source payment records
|
|||||
| SUBLOCADE Normalized: sublocade |
Drug | Indivior Inc. | $28.66 | 1 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $26.95 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $26.20 | 2 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE Normalized: freestyle libre |
Device | Abbott Laboratories | $20.60 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.35 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.39 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $14.61 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 91 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 246 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 44 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 17 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
57 | 23 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
23 | 14 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
91 | 34 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
44 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
246 | 51 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 352 | 123 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 315 | 113 |
| Levothyroxine Sodium | Levothyroxine Sodium | 263 | 88 |
| Losartan Potassium | Losartan Potassium | 262 | 88 |
| Ozempic | Semaglutide | 246 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 245 | 88 |
| Lisinopril | Lisinopril | 233 | 85 |
| Metoprolol Succinate | Metoprolol Succinate | 190 | 70 |
| Metformin Hcl | Metformin Hcl | 165 | 60 |
| Famotidine | Famotidine | 144 | 53 |
| Omeprazole | Omeprazole | 144 | 59 |
| Gabapentin | Gabapentin | 139 | 49 |
| Synjardy | Empagliflozin/Metformin Hcl | 134 | 22 |
| Tamsulosin Hcl | Tamsulosin Hcl | 130 | 53 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 41 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 101 | 37 |
| Fluticasone Propionate | Fluticasone Propionate | 98 | 41 |
| Myrbetriq | Mirabegron | 98 | 37 |
| Meloxicam | Meloxicam | 96 | 44 |
| Farxiga | Dapagliflozin Propanediol | 91 | 34 |
| Simvastatin | Simvastatin | 87 | 35 |
| Furosemide | Furosemide | 84 | 35 |
| Montelukast Sodium | Montelukast Sodium | 82 | 31 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 32 |
| Baclofen | Baclofen | 76 | 41 |
| Pantoprazole Sodium | Pantoprazole Sodium | 73 | 34 |
| Trazodone Hcl | Trazodone Hcl | 72 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 71 | 26 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 70 | 66 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 18 |
| Memantine Hcl | Memantine Hcl | 60 | 21 |
| Linzess | Linaclotide | 57 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 51 | 19 |
| Pregabalin | Pregabalin | 50 | suppressed |
| Alprazolam | Alprazolam | 48 | suppressed |
| Azithromycin | Azithromycin | 48 | 47 |
| Glipizide | Glipizide | 48 | 17 |
| Tramadol Hcl | Tramadol Hcl | 48 | 17 |
| Fenofibrate | Fenofibrate Nanocrystallized | 47 | 18 |
| Escitalopram Oxalate | Escitalopram Oxalate | 46 | 12 |
| Paroxetine Hcl | Paroxetine Hcl | 46 | 14 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 45 | 25 |
| Donepezil Hcl | Donepezil Hcl | 44 | 17 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | 12 |
| Sertraline Hcl | Sertraline Hcl | 40 | 12 |
| Valsartan | Valsartan | 39 | 13 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 37 | 17 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 32 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 36 | 14 |
| Meclizine Hcl | Meclizine Hcl | 36 | 16 |
| Jardiance | Empagliflozin | 34 | 11 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 32 | 28 |
| Ibuprofen | Ibuprofen | 32 | 21 |
| Ondansetron Odt | Ondansetron | 32 | 16 |
| Pioglitazone Hcl | Pioglitazone Hcl | 32 | 13 |
| Alendronate Sodium | Alendronate Sodium | 30 | 14 |
| Finasteride | Finasteride | 29 | 11 |
| Fluconazole | Fluconazole | 28 | 16 |
| Xigduo Xr | Dapaglifloz Propaned/Metformin | 27 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 27 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 26 | suppressed |
| Clonazepam | Clonazepam | 25 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 25 | suppressed |
| Naproxen | Naproxen | 24 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 24 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 24 | suppressed |
| Phenobarbital | Phenobarbital | 23 | suppressed |
| Prolia | Denosumab | 23 | 14 |
| Allopurinol | Allopurinol | 22 | suppressed |
| Tradjenta | Linagliptin | 22 | suppressed |
| Carvedilol | Carvedilol | 21 | suppressed |
| Mounjaro | Tirzepatide | 21 | suppressed |
| Nystatin | Nystatin | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 20 | suppressed |
| Levofloxacin | Levofloxacin | 20 | 16 |
| Potassium Chloride | Potassium Chloride | 20 | suppressed |
| Risperidone | Risperidone | 20 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 20 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 19 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | 12 |
| Dutasteride | Dutasteride | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 18 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 18 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 18 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 18 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 17 | suppressed |
| Cephalexin | Cephalexin | 17 | 17 |
| Diclofenac Sodium | Diclofenac Sodium | 17 | 15 |
| Duloxetine Hcl | Duloxetine Hcl | 17 | suppressed |
| Vraylar | Cariprazine Hcl | 17 | suppressed |
| Euthyrox | Levothyroxine Sodium | 16 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 16 | 16 |
| Pravastatin Sodium | Pravastatin Sodium | 16 | suppressed |
| Rybelsus | Semaglutide | 16 | suppressed |
| Topiramate | Topiramate | 16 | suppressed |
| Eliquis | Apixaban | 15 | suppressed |
| Glipizide Er | Glipizide | 15 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 14 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 13 | suppressed |
| Colchicine | Colchicine | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Estradiol | Estradiol | 13 | suppressed |
| Methylprednisolone | Methylprednisolone | 13 | suppressed |
| Novolog Flexpen | Insulin Aspart | 13 | suppressed |
| Rexulti | Brexpiprazole | 13 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 13 | suppressed |
| Fesoterodine Fumarate Er | Fesoterodine Fumarate | 12 | suppressed |
| Lactulose | Lactulose | 12 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 11 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 11 | suppressed |
| Xarelto | Rivaroxaban | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $581.13 · 37 records | Novo Nordisk Inc | AIRSUPRA, AREXVY, Dexcom G6 Transmitter, FARXIGA, FREESTYLE LIBRE, FREESTYLE LIBRE 3, OTEZLA, Ozempic, REPATHA, REXULTI, Rybelsus, SHINGRIX, SUBLOCADE, TRELEGY ELLIPTA, VRAYLAR, Wegovy | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error